世界の代謝障害治療市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Metabolic Disorders Therapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3714 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥546,000 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥819,000 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,092,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、代謝障害治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（異染性白質ジストロフィー、球状白質ジストロフィー、肝性脳症、その他）、用途別市場規模（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・代謝障害治療の市場動向 ・企業の競争状況、市場シェア ・代謝障害治療の種類別市場規模（異染性白質ジストロフィー、球状白質ジストロフィー、肝性脳症、その他） ・代謝障害治療の用途別市場規模（糖尿病、肥満、高コレステロール血症、リソソーム蓄積症、その他） ・代謝障害治療の北米市場規模2016-2027（アメリカ、カナダ） ・代謝障害治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・代謝障害治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・代謝障害治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・代謝障害治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AbbVie、Novo Nordisk、Actelion Pharmaceuticals、Sanofi、Biocon、Merck、Boehringer Ingelheim、AstraZeneca、CymaBay Therapeutics、Eli Lilly and Company） ・結論

Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes.
Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the forecast period.

Market Analysis and Insights: Global Metabolic Disorders Therapeutics Market
The global Metabolic Disorders Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metabolic Disorders Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metabolic Disorders Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metabolic Disorders Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metabolic Disorders Therapeutics market.

Global Metabolic Disorders Therapeutics Scope and Market Size
Metabolic Disorders Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metabolic Disorders Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Metachromatic Leukodystrophy
Globoid Leukodystrophy
Hepatic Encephalopathy
Others

Segment by Application
Diabetes
Obesity
Hypercholesterolemia
Lysosomal Storage Diseases
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Metachromatic Leukodystrophy
1.2.3 Globoid Leukodystrophy
1.2.4 Hepatic Encephalopathy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Metabolic Disorders Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Diabetes
1.3.3 Obesity
1.3.4 Hypercholesterolemia
1.3.5 Lysosomal Storage Diseases
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Metabolic Disorders Therapeutics Market Perspective (2016-2027)
2.2 Metabolic Disorders Therapeutics Growth Trends by Regions
2.2.1 Metabolic Disorders Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Metabolic Disorders Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Metabolic Disorders Therapeutics Industry Dynamic
2.3.1 Metabolic Disorders Therapeutics Market Trends
2.3.2 Metabolic Disorders Therapeutics Market Drivers
2.3.3 Metabolic Disorders Therapeutics Market Challenges
2.3.4 Metabolic Disorders Therapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorders Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disorders Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
3.4 Global Metabolic Disorders Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Therapeutics Revenue in 2020
3.5 Metabolic Disorders Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disorders Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disorders Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Metabolic Disorders Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disorders Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2022-2027)

5 Metabolic Disorders Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disorders Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Metabolic Disorders Therapeutics Market Size (2016-2027)
6.2 North America Metabolic Disorders Therapeutics Market Size by Type
6.2.1 North America Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
6.3 North America Metabolic Disorders Therapeutics Market Size by Application
6.3.1 North America Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
6.4 North America Metabolic Disorders Therapeutics Market Size by Country
6.4.1 North America Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Metabolic Disorders Therapeutics Market Size (2016-2027)
7.2 Europe Metabolic Disorders Therapeutics Market Size by Type
7.2.1 Europe Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
7.3 Europe Metabolic Disorders Therapeutics Market Size by Application
7.3.1 Europe Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
7.4 Europe Metabolic Disorders Therapeutics Market Size by Country
7.4.1 Europe Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type
8.2.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application
8.3.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region
8.4.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Metabolic Disorders Therapeutics Market Size (2016-2027)
9.2 Latin America Metabolic Disorders Therapeutics Market Size by Type
9.2.1 Latin America Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Metabolic Disorders Therapeutics Market Size by Application
9.3.1 Latin America Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Metabolic Disorders Therapeutics Market Size by Country
9.4.1 Latin America Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type
10.2.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application
10.3.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country
10.4.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Details
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Metabolic Disorders Therapeutics Introduction
11.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.1.5 AbbVie Recent Development
11.2 Novo Nordisk
11.2.1 Novo Nordisk Company Details
11.2.2 Novo Nordisk Business Overview
11.2.3 Novo Nordisk Metabolic Disorders Therapeutics Introduction
11.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.2.5 Novo Nordisk Recent Development
11.3 Actelion Pharmaceuticals
11.3.1 Actelion Pharmaceuticals Company Details
11.3.2 Actelion Pharmaceuticals Business Overview
11.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Introduction
11.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.3.5 Actelion Pharmaceuticals Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Metabolic Disorders Therapeutics Introduction
11.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.4.5 Sanofi Recent Development
11.5 Biocon
11.5.1 Biocon Company Details
11.5.2 Biocon Business Overview
11.5.3 Biocon Metabolic Disorders Therapeutics Introduction
11.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.5.5 Biocon Recent Development
11.6 Merck
11.6.1 Merck Company Details
11.6.2 Merck Business Overview
11.6.3 Merck Metabolic Disorders Therapeutics Introduction
11.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.6.5 Merck Recent Development
11.7 Boehringer Ingelheim
11.7.1 Boehringer Ingelheim Company Details
11.7.2 Boehringer Ingelheim Business Overview
11.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Introduction
11.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.7.5 Boehringer Ingelheim Recent Development
11.8 AstraZeneca
11.8.1 AstraZeneca Company Details
11.8.2 AstraZeneca Business Overview
11.8.3 AstraZeneca Metabolic Disorders Therapeutics Introduction
11.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.8.5 AstraZeneca Recent Development
11.9 CymaBay Therapeutics
11.9.1 CymaBay Therapeutics Company Details
11.9.2 CymaBay Therapeutics Business Overview
11.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Introduction
11.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.9.5 CymaBay Therapeutics Recent Development
11.10 Eli Lilly and Company
11.10.1 Eli Lilly and Company Company Details
11.10.2 Eli Lilly and Company Business Overview
11.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Introduction
11.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2016-2021)
11.10.5 Eli Lilly and Company Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Metachromatic Leukodystrophy
Table 3. Key Players of Globoid Leukodystrophy
Table 4. Key Players of Hepatic Encephalopathy
Table 5. Key Players of Others
Table 6. Global Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Metabolic Disorders Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Metabolic Disorders Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Metabolic Disorders Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Metabolic Disorders Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Metabolic Disorders Therapeutics Market Share by Regions (2022-2027)
Table 12. Metabolic Disorders Therapeutics Market Trends
Table 13. Metabolic Disorders Therapeutics Market Drivers
Table 14. Metabolic Disorders Therapeutics Market Challenges
Table 15. Metabolic Disorders Therapeutics Market Restraints
Table 16. Global Metabolic Disorders Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Metabolic Disorders Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorders Therapeutics as of 2020)
Table 19. Ranking of Global Top Metabolic Disorders Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Metabolic Disorders Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Metabolic Disorders Therapeutics Product Solution and Service
Table 23. Date of Enter into Metabolic Disorders Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Metabolic Disorders Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Metabolic Disorders Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Metabolic Disorders Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. AbbVie Company Details
Table 64. AbbVie Business Overview
Table 65. AbbVie Metabolic Disorders Therapeutics Product
Table 66. AbbVie Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 67. AbbVie Recent Development
Table 68. Novo Nordisk Company Details
Table 69. Novo Nordisk Business Overview
Table 70. Novo Nordisk Metabolic Disorders Therapeutics Product
Table 71. Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Novo Nordisk Recent Development
Table 73. Actelion Pharmaceuticals Company Details
Table 74. Actelion Pharmaceuticals Business Overview
Table 75. Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product
Table 76. Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Actelion Pharmaceuticals Recent Development
Table 78. Sanofi Company Details
Table 79. Sanofi Business Overview
Table 80. Sanofi Metabolic Disorders Therapeutics Product
Table 81. Sanofi Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Sanofi Recent Development
Table 83. Biocon Company Details
Table 84. Biocon Business Overview
Table 85. Biocon Metabolic Disorders Therapeutics Product
Table 86. Biocon Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Biocon Recent Development
Table 88. Merck Company Details
Table 89. Merck Business Overview
Table 90. Merck Metabolic Disorders Therapeutics Product
Table 91. Merck Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 92. Merck Recent Development
Table 93. Boehringer Ingelheim Company Details
Table 94. Boehringer Ingelheim Business Overview
Table 95. Boehringer Ingelheim Metabolic Disorders Therapeutics Product
Table 96. Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Boehringer Ingelheim Recent Development
Table 98. AstraZeneca Company Details
Table 99. AstraZeneca Business Overview
Table 100. AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 101. AstraZeneca Recent Development
Table 102. CymaBay Therapeutics Company Details
Table 103. CymaBay Therapeutics Business Overview
Table 104. CymaBay Therapeutics Metabolic Disorders Therapeutics Product
Table 105. CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 106. CymaBay Therapeutics Recent Development
Table 107. Eli Lilly and Company Company Details
Table 108. Eli Lilly and Company Business Overview
Table 109. Eli Lilly and Company Metabolic Disorders Therapeutics Product
Table 110. Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2016-2021) & (US$ Million)
Table 111. Eli Lilly and Company Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorders Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Metachromatic Leukodystrophy Features
Figure 3. Globoid Leukodystrophy Features
Figure 4. Hepatic Encephalopathy Features
Figure 5. Others Features
Figure 6. Global Metabolic Disorders Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Diabetes Case Studies
Figure 8. Obesity Case Studies
Figure 9. Hypercholesterolemia Case Studies
Figure 10. Lysosomal Storage Diseases Case Studies
Figure 11. Others Case Studies
Figure 12. Metabolic Disorders Therapeutics Report Years Considered
Figure 13. Global Metabolic Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 14. Global Metabolic Disorders Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 15. Global Metabolic Disorders Therapeutics Market Share by Regions: 2020 VS 2027
Figure 16. Global Metabolic Disorders Therapeutics Market Share by Regions (2022-2027)
Figure 17. Global Metabolic Disorders Therapeutics Market Share by Players in 2020
Figure 18. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metabolic Disorders Therapeutics as of 2020
Figure 19. The Top 10 and 5 Players Market Share by Metabolic Disorders Therapeutics Revenue in 2020
Figure 20. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2016-2021)
Figure 21. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2022-2027)
Figure 22. North America Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. North America Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 24. North America Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 25. North America Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 26. United States Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Canada Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 30. Europe Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 31. Europe Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 32. Germany Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. France Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. U.K. Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Italy Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Russia Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Nordic Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 40. Asia-Pacific Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 41. Asia-Pacific Metabolic Disorders Therapeutics Market Share by Region (2016-2027)
Figure 42. China Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Japan Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. South Korea Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Southeast Asia Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. India Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Australia Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 50. Latin America Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 51. Latin America Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 52. Mexico Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Brazil Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Metabolic Disorders Therapeutics Market Share by Type (2016-2027)
Figure 56. Middle East & Africa Metabolic Disorders Therapeutics Market Share by Application (2016-2027)
Figure 57. Middle East & Africa Metabolic Disorders Therapeutics Market Share by Country (2016-2027)
Figure 58. Turkey Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Saudi Arabia Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. UAE Metabolic Disorders Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. AbbVie Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 62. Novo Nordisk Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 63. Actelion Pharmaceuticals Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 64. Sanofi Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 65. Biocon Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 66. Merck Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 67. Boehringer Ingelheim Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 68. AstraZeneca Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 69. CymaBay Therapeutics Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 70. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---